Case report: cobblestone

Neuropsychiatric reaction induced by clarithromycin in a patient on highly active antiretroviral therapy (HAART)

K Prime, P French

Case history
A 58 year old man, diagnosed HIV-1 antibody positive 3 years previously, presented with a 24 hour history of hyperactivity. This culminated in the development of suicidal and homicidal ideation. For fear of injury to himself and others he was admitted to hospital.

He had commenced a course of clarithromycin by mouth 500 mg twice daily 10 days previously, for a bacterial chest infection. Two months before this, HAART had been commenced with zidovudine by mouth 250 mg twice daily, didanosine by mouth 200 mg twice daily, and nevirapine by mouth 200 mg twice daily. This was in addition to long term treatment with simvastatin by mouth 20 mg once daily for hypercholesterolaemia. There was no other medical history of note. He also had no previous history of mental ill health, alcohol, or drug misuse.

On physical examination, he was afebrile with oxygen saturations of 100% on air. His pulse was regular at 80 beats/minute and blood pressure 110/60 mm Hg. Examination of his respiratory and gastrointestinal systems was unremarkable apart from mental state assessment which showed hyperactivity manifested as pressure of speech, poor concentration, and extreme anxiety. He also expressed suicidal and homicidal ideation into which he maintained insight.

Investigations including full blood count, urea and electrolytes, liver function tests, calcium, phosphate, and glucose were normal. Blood culture, Toxoplasma gondii serology, treponemal haemagglutination assay, and serum cryptococcal antigen were negative. HIV viral load was <500 copies/ml and CD4 count 480 x 10^6/l. Drug levels were not measured.

A diagnosis of a severe neuropsychiatric reaction secondary to clarithromycin was made. Clarithromycin was discontinued and he was treated with diazepam by mouth 5 mg twice daily and temazepam by mouth 20 mg at night. Twenty four hours after admission he remained only mildly hyperactive with no further suicidal or homicidal ideation. After 72 hours his symptoms had resolved completely and he was discharged.

Discussion
Clarithromycin, a macrolide antibiotic, and nevirapine, a non-nucleoside reverse transcriptase inhibitor, are principally metabolised in the liver by the cytochrome P450 isoenzymes of the CYP3A family. The major presystemic active metabolite of clarithromycin is the R-epimer of 14-OH-6-0-methylerythromycin A. Clarithromycin is an inhibitor of CYP3A and its use in patients concurrently taking drugs metabolised by the cytochrome P450 system may be associated with elevations in their serum levels. Nevirapine acts as a mild to moderate enzyme inducer of CYP3A. It may therefore not only reduce plasma concentrations of other drugs metabolised by the same system but also acts as an autoinducer, with steady state reached after 7-9 days.

The principal side effects of clarithromycin are gastrointestinal; however, less commonly, CNS side effects have been reported, including dizziness, vertigo, anxiety, insomnia, tinnitus, confusion, disorientation, hallucinations, psychosis, and depersonalisation. At the time of writing the Committee on Safety of Medicines (CSM)/Medicines Control Agency (MCA) have received 219 reports of suspected clarithromycin induced psychiatric disorders including psychosis (n=5), depersonalisation (n=5), and suicidal ideation (n=4) (CSM, personal communication). It has been postulated that macrolide antibiotics may cause a psychosis-like syndrome via their inhibitory action on glutamatergic neurotransmission in the brain. Nevirapine has not been reported to cause serious CNS adverse effects.

In one study (n=18), concomitant administration of clarithromycin and nevirapine resulted in a 28% significant increase in nevirapine C_max and a non-significant 26% increase in nevirapine area under the curve (AUC) and C_max (24%), with no notable adverse effects. There was also a significant reduction in clarithromycin AUC (30%) with a 58% significant
increase in AUC of its active 14-OH metabo-
lite. A similar interaction study (n=15) con-
figured these results although AUC increase
of the active metabolite 14-OH clarithromycin
was only 27%.

To date, the CSM/MCA have received no
reports of suspected interactions between
either zidovudine, didanosine or simvastatin
and clarithromycin or nevirapine.

We therefore postulate that the accumula-
tion of the active 14-OH metabolite of clarithromy-
cin caused the acute neuropsychiatric reaction
observed in our patient. The mechanism for
this reaction is not clear.

Clarithromycin is frequently used in the
treatment of bacterial respiratory tract infec-
tions and disseminated Mycobacterium avium
complex infection in HIV positive individuals.

We wish to alert physicians to the potential for
interactions between established drugs with
well documented side effects, such as mac-
rolide antibiotics, and the much newer classes
of antiretroviral agents (ARVs) used in the
treatment of HIV infection.

We thank Professor David Back and Sara Gibbons at the
Department of Pharmacology and Therapeutics, University of
Liverpool, for their helpful comments and advice regarding this
paper; and the patient and staff on the Patrick Manson Unit for
permission to report this case.

Competing interests: None declared.

1 Abbott Laboratories, 2000. Clarithromycin: summary of prod-
cuct characteristics. Available from the ABPI compendium of
data sheets and SPCs 1999–2000.
2 Manev H, Favaron M. Macrolide antibiotics protect
neurons in culture against the N-methyl-D-aspartate
receptor-mediated toxicity of glutamate. Brain Res 1993;
624:331–5.
3 Boehringer Ingelheim International, April 2000. Viramune:
summary of product characteristics. Available from http://
www.eudra.org/humandocs/humans/EPAR/Viramune/
Viramune.htm
4 Robinson P, Gigiotti M. Effects of the reverse transcriptase
inhibitor, nevirapine, on the steady-state pharmacokinetics
of clarithromycin in HIV-positive patients. 6th Conference
on Retroviruses and Opportunistic Infections, Chicago
1999. (Abstract 374.)
Neuropsychiatric reaction induced by clarithromycin in a patient on highly active antiretroviral therapy (HAART)

K Prime and P French

Sex Transm Infect 2001 77: 297-298
doi: 10.1136/sti.77.4.297

Updated information and services can be found at:
http://sti.bmj.com/content/77/4/297

These include:

References
This article cites 1 articles, 0 of which you can access for free at:
http://sti.bmj.com/content/77/4/297#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

- Drugs: infectious diseases (3182)
- HIV / AIDS (2514)
- HIV infections (2514)
- HIV/AIDS (2514)
- Ear, nose and throat/otolaryngology (17)
- Health education (960)
- Travel medicine (36)
- Tropical medicine (infectious diseases) (23)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/